Effects of different doses of long-acting growth hormone in treating children with growth hormone deficiency

Figure 1 Evolution of growth velocity and height standard deviation score following polyethylene glycol recombinant human growth hormone treatment. A: Depicts the alterations in growth velocity among growth hormone deficiency patients after 1 and 2 years of polyethylene glycol recombinant human growth hormone (PEG-rhGH) treatment at varying doses; B: Illustrates the modifications in height standard deviation score after 1 and 2 years of PEG-rhGH treatment at diverse doses; C: Presents changes in serum insulin-like growth factor-1 concentrations one-year post-treatment with PEG-rhGH at different doses; D: Showcases the variations in serum insulin-like growth factor-binding protein-3 (IGFBP-3) levels one year after PEG-rhGH treatment at varying doses. HDG: High-dose group; LDG: Low-dose group; GV: Growth velocity; HtSDS: Height standard deviation score.

Figure 2 Alterations in Physiological Markers Following polyethylene glycol recombinant human growth hormone Treatment. A: Illustrates the variations in serum insulin-like growth factor-1 concentrations one-year post-treatment with polyethylene glycol recombinant human growth hormone (PEG-rhGH) at different doses; B: Depicts changes in serum insulin-like growth factor-binding protein-3 levels one year after treatment with PEG-rhGH at varying doses; C: Showcases the modifications in bone age one year after treatment with PEG-rhGH at diverse doses. HDG: High-dose group; LDG: Low-dose group; IGF-1: Insulin-like growth factor-1; IGFBP-3: Insulin-like growth factor-binding protein-3; BA: Bone age; CA: Chronological age.